

RECEIVED
CENTRAL FAX CENTER
JUL 13 2006**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) An oral pharmaceutical dosage form comprising:

(a) a core material comprising ~~[that contains]~~ a proton pump inhibitor, at least one ~~[or more]~~ alkaline reacting compound ~~[compound(s)]~~ and optionally pharmaceutically acceptable excipients ~~[having]~~,

(b) a water soluble separating layer, and

(c) a ~~[an enteric]~~ coating layer comprising at least one enteric polymer,

wherein, ~~[characterized in that]~~ the core material is alkaline reacting, and upon application of the coating layer on the core material, ~~[that]~~ the separating layer is ~~[being]~~ formed in situ ~~[during the enteric coating]~~ as a water soluble salt product between the enteric polymer ~~[coating layer-polymer(s)]~~ and the alkaline reacting compound ~~[compound(s)]~~.

2. (Currently amended) The [A] dosage form according to claim 1, wherein the alkaline reacting compound is ~~[compounds are]~~ selected from the group consisting of an alkaline reacting organic compound ~~[substances]~~, a hydroxide ~~[hydroxides]~~ of an alkali metal, an ~~[metals or one of their]~~ alkaline salt ~~[salts]~~ of phosphoric acid, an alkaline salt of carbonic acid, an alkaline salt of ~~[or]~~ silicic acid, and ~~[or]~~ an alkaline ammonium salt.

3. (Currently amended) The [A] dosage form according to claim 2, wherein the alkaline reacting compound ~~[substance]~~ is selected from the group consisting of a hydroxide of an alkali metal, ~~[or]~~ an alkaline salt of phosphoric acid, an alkaline salt of carbonic acid, an alkaline salt of ~~[or]~~ silicic acid, and ~~[or]~~ an alkaline ammonium salt.

4. (Currently amended) The [A] dosage form according to claim 2, wherein the alkaline reacting ~~[compound is an alkaline]~~ organic compound is ~~[substance, e.g.]~~ an amino acid or a salt thereof ~~[, an alkaline amine or a derivative thereof, or an alkaline salt of a weak organic acid]~~.

USSN10/693,31, filed October 23, 2003
 Attorney Docket No. 1103326-0203 CON
 Page 4 of 10

5. (Currently amended) The [A] dosage form according to claim 3 [2], wherein the ~~[alkaline organic substance is an]~~ amino acid is selected from the group consisting of [~~;-e.g.;~~ lysine, arginine, ornithine and [~~or~~] histidine [~~;-or an alkaline amine or a derivative thereof, e.g. N-methyl-D-glucamine or trometamine~~].

6. (Currently amended) The [A] dosage form according to claim 1, wherein the alkaline reacting compound is [~~compounds are~~] present in a concentration of more than 0.1 mmol/g dry ingredients in the alkaline containing part of the core material.

7. (Currently amended) The [A] dosage form according to claim 1, wherein the enteric polymer is a [~~coating polymer(s) is/are~~] hydroxypropyl cellulose derivative [~~derivative(s); e.g. hydroxypropylmethylcellulose acetate succinate~~].

8. (Currently amended) The [A] dosage form according to claim 1, wherein the enteric coating polymer is a copolymer of methacrylic acid or methylmethacrylate ester [~~copolymerized methacrylic acid/methacrylic acid-methyl esters~~].


9. (Currently amended) The [A] dosage form according to claim 1, wherein the proton pump inhibitor is a compound of the general formula I or a pharmaceutically acceptable salt thereof or a pure enantiomer thereof in neutral form or in the form of an alkaline salt




wherein

USSN10/693,31, filed October 23, 2003
 Attorney Docket No. 1103326-0203 CON
 Page 5 of 10


Het₁ is




or




Het₂ is




or



X -



or



wherein N in the benzimidazole moiety means that one of the carbon atoms substituted by R₆-R₉ [optionally] may be exchanged for a nitrogen atom without any substituents;

R₁, R₂ and R₃ are the same or different and selected from the group consisting of hydrogen, alkyl, unsubstituted alkoxy, alkoxy [optionally] substituted by fluorine, alkythio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R₄ and R₅ are the same or different and selected from hydrogen, alkyl and aralkyl;

R₆' is selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

USSN10/693,31, filed October 23, 2003
 Attorney Docket No. 1103326-0203 CON
 Page 6 of 10

R₆-R₉ are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, and trifluoroalkyl, or adjacent groups R₆-R₉ form ring structures which may be further substituted;

R₁₀ is hydrogen or forms an alkylene chain together with R₃ and

R₁₁ and R₁₂ are the same or different and selected from the group consisting of hydrogen, halogen, [or] alkyl and [~~alkyl groups,~~] alkoxy, which alkyl or alkoxy [~~groups and moieties thereof~~] may be branched or a [~~and~~] straight C₁-C₉-chain [~~chains~~] or a [~~comprise~~] cyclic alkyl [~~groups, for example cycloalkylalkyl~~].

10. (Currently amended) The [A] dosage form according to claim 1, wherein the proton pump inhibitor is omeprazole or an alkaline salt thereof.

11. (Currently amended) The [A] dosage form according to claim 1, wherein the proton pump inhibitor is a pure enantiomer of omeprazole or an alkaline salt thereof.

12. (Currently amended) The [A] dosage form according to claim 1, wherein the proton pump inhibitor is lansoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

13. (Currently amended) The [A] dosage form according to claim 1, wherein the proton pump inhibitor is pantoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

14. (Currently amended) The [A] dosage form according to claim 1, wherein the [~~alkaline reacting~~] core material is in the form of individual pellets [~~intended for a capsule formulation or a tableted multiple-unit dosage form~~].

15. (Currently amended) The [A] dosage form according to claim 1, wherein the [~~alkaline reacting~~] core material is a tablet.

USSH10/693,31, filed October 23, 2003
Attorney Docket No. 1103326-0203 CON
Page 7 of 10

16. (Currently amended) The [A] dosage form according to claim 14 [~~1~~], wherein individually enteric coated pellets are compressed into a tableted multiple unit dosage form.

17. (Currently amended) A process for the preparation of an oral, enteric coated pharmaceutical dosage form comprising the steps of:

forming a core material comprising [~~that contains~~] a proton pump inhibitor, at least one [~~or more~~] alkaline reacting compounds and optionally pharmaceutically acceptable excipients, and
applying a coating layer comprising at least one enteric polymer so as to surround the core material thereby forming in situ [~~having a water soluble~~] separating layer as a water soluble product between the alkaline compound and the enteric polymer [~~and an enteric coating layer characterized in that an alkaline reacting core material is prepared and coated with an enteric coating polymer wherein a separating layer between the core material and the enteric coating layer is formed in situ by a reaction between the enteric coating polymer(s) and the alkaline reacting compound(s) in the core material during the application of the enteric coating onto the alkaline reacting core material~~].

18. (Canceled)

19. (Currently amended) A method for inhibiting gastric acid secretion comprising [~~in mammals and man by~~] administering [~~to a host in need thereof a dosage form comprising~~] a therapeutically effective amount of a dosage form [~~dose of a proton pump inhibitor~~] as defined in any of claims 1-16 to a patient in need thereof.

20. (Cancelled)

21. (New) The dosage form according to claim 2, wherein the alkaline reacting organic compound is an alkaline amine or a derivative thereof.

USSN10/693,31, filed October 23, 2003
Attorney Docket No. 1103326-0203 CON
Page 8 of 10

22. (New) The dosage form according to claim 21, wherein the derivative of the alkaline amine is N-methyl-D-glucamine or trometamine.

23. (New) The dosage form according to claim 2, wherein the alkaline reacting organic compound is an alkaline salt of a weak organic acid.

24. (New) The dosage form according to claim 7, wherein the hydroxypropyl cellulose derivative is hydroxypropylmethylcellulose acetate succinate.